Company Information

INDOCO REMEDIES LTD.

NSE : INDOCOBSE : 532612ISIN CODE : INE873D01024Industry : Pharmaceuticals & DrugsHouse : Private
BSE330.152.35 (+0.72 %)
PREV CLOSE ( ) 327.80
OPEN PRICE ( ) 329.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1964
TODAY'S LOW / HIGH ( )328.05 334.30
52 WK LOW / HIGH ( )307 416.95
NSE329.451.45 (+0.44 %)
PREV CLOSE( ) 328.00
OPEN PRICE ( ) 329.70
BID PRICE (QTY) 329.45 (15)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 46917
TODAY'S LOW / HIGH( ) 328.50 334.10
52 WK LOW / HIGH ( )306.4 415
ChairmanSuresh G Kare
Managing DirectorAditi Panandikar
Company SecretaryRamanathan Hariharan
Non Executive DirectorAnand Nadkarni
Joint Managing DirectorSundeep V Bambolkar
Non Executive Independent DirectorVasudha V Kamat
Abhijit Y Gore
Incorporation Year : 1947

Registered Office :

Address : Indoco House,166 C S T Road,Kalina , Santacruz (East) Mumbai,
Maharashtra-400098 .

Phone : 022-62871000 / 68791250

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,MCX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.